Information about Trospium
Liver safety of Trospium
Trospium has not been implicated in causing liver enzyme elevations or clinically apparent acute liver injury.
Mechanism of action of Trospium
Trospium (trose' pee um) is a synthetic anticholinergic agent that inhibits muscarinic actions of acetylcholine on autonomic nerve endings, decreasing secretions and inhibiting gastrointestinal and bladder motility. Trospium increases bladder capacity and decreases bladder contractions and the urgency of urination.
FDA approval information for Trospium
Trospium was approved for use in the United States in 1975 and indications include urinary urge incontinence and symptoms of overactive bladder such as urinary urgency and frequency. Trospium is available in tablets of 20 mg in generic forms and under the brand name Sanctura.
Dosage and administration for Trospium
The recommended adult oral dose is 20 once or twice daily. Common side effects are those of parasympathetic stimulation and include dryness of the mouth and eyes, decreased sweating, headache, visual blurring, constipation, urinary retention, restlessness, confusion and hallucinations. anticholinergic agents can precipitate acute narrow angle glaucoma and acute urinary retention.
- Overactive bladder syndrome agents - darifenacin, fesoterodine, flavoxate, hyoscyamine, mirabegron, oxybutynin, solifenacin, tolterodine, trospium